Sorrento Says FDA Authorized Phase 1 Trial in Multiple Myeloma
By Michael Dabaie
Sorrento Therapeutics Inc. said the U.S. Food and Drug
Administration authorized it to start a Phase 1 clinical trial of
its anti-CD38 Dimeric Antigen Receptor-T Cell therapy for relapsed
or refractory multiple myeloma.
The proprietary CD38 DAR-T cell therapy candidate demonstrated
strong cytotoxic activity in preclinical studies, the company
Sorrento said the DAR-T technology is readily adaptable to
dozens of cancer targets.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
August 02, 2021 09:46 ET (13:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.